

Table S1 Patient's general characteristics, operative data and outcomes in reports with ≥8 patients

Authors	Year	Country	N	Increase FLR (%)	Hospital stay, day	Morbidity (%)	Major morbidity (%)	Mortality (%)	Follow-up, months	OFS (%)	OS (%)
Schnitzbauer <i>et al.</i> (5)	2012	Multicenter Germany	25	74	NR	68	44 ⁺⁺	12	6 [2–25.9]	80	86 [^]
Machado <i>et al.</i> (44)	2012	Single Center Brazil	8	88 [†]	NR	NR	NR	0 [†]	NR	NR	NR
Donati <i>et al.</i> (71)	2012	Single Center Germany	8	NR	NR	NR	NR	NR	NR	NR	NR
Dokmak <i>et al.</i> (72)	2012	Single Center France	8	70	42 [25–56]	90	NR	NR	NR	NR	NR
Torres <i>et al.</i> (54)	2013	Multicenter Brazil	39	83	17.8 [13–40]	NR	59	12.8	NR	NR	NR
Li <i>et al.</i> (73)	2013	Single Center Germany	9	87.2	NR	100	31.2	22.2	NR	NR	NR
Robles <i>et al.</i> (36)	2014	Single Center Spain	22	61	16 [12–28]	NR	NR	9.1	6 [2–22]	95	100 [*]
Nadalini <i>et al.</i> (7)	2015	Single Center Germany	15	87.2	NR	66.7	49.1 ⁺⁺	28.7	17 [1–33]	NR	66.6 ⁻⁻⁻
Schadde <i>et al.</i> (46)	2015	Multicenter International ALPPS registry	320	NR	NR	7.2 (±1.9) ^{//}	NR	8.8 ^{^^}	3 ^B	NR	NR
Truant <i>et al.</i> (19)	2015	Multicenter Franco-Belgian	62	48.6	29.2 [3–129]	80.6 ^{^^}	40.3 ^{^^}	12.9 ^{^^}	NR	NR	NR
Hernandez-Alejandro <i>et al.</i> (63)	2015	Single Center Canada	14	93	18 [23±12] ^C	36	14 ⁺	0	9.4	85.7 ^D	100
Ratti <i>et al.</i> (55)	2015	Multicenter Italy	12	47	24 [16–42]	NR	41.7	8.3	12 [6–18]	67 ⁻	92 ⁻
Lang <i>et al.</i> (14)	2015	Single Center Germany	16	85.5	30 [16–90]	81.2	31.3 ⁺	12.5	26.4 [3.2–54.3]	NR ^E	48.9 ⁻
Alvarez <i>et al.</i> (39)	2015	Single Center Argentina	30	89.7	16 [11–62]	53	43	6.6	17 [1.5–33] ^F	40 [^]	63 [^]
Serenari <i>et al.</i> (56)	2016	Multicenter Italy	50	63	27 [15–127]	NR	54	20 ^{^^}	12.1	55/45/62 ^{***}	91/60/75 ^{***}
Bjornsson <i>et al.</i> (74)	2016	Multicenter Sweden-Norway	23	64.3	9 [2–50] ^{**}	91	43.5	4.3 ^{^^}	22.5	27 ⁻	59 [^]
Vivarelli <i>et al.</i> (75)	2016	Single Center Italy	9	96	22 [13–55]	67	44	11.1 ⁻	17.1 [8.6–25.6] ^F	75 ⁻	89 ⁻
Vennarecci <i>et al.</i> (76)	2016	Multicenter Italy	13	71.7–64.8 [/]	22 [20–67]– 33 [26–66] [/]	NR ^{^^^}	NR ^{^^^}	23.1 ^{^^}	15 [1–27]	42 ⁻	74 ⁻
Wanis <i>et al.</i> (60)	2017	Multicenter USA–Canada– Argentina	47	NR	NR	37	21	0	35	50/16/13 ^{^---}	93/66/50 ^{^---}
Linecker <i>et al.</i> (58)	2017	Multicenter International ALPPS registry	437	91	12 [8–19]	56	3	3.8	3	NR	NR
Vennarecci <i>et al.</i> (77)	2018	Italian	24	68.4	29 [15–68]	48 [#]	4 [#]	8.3 ^{^^}	10 [2–54]	47.3 [^]	47.5 [^]
Sandström <i>et al.</i> (52)	2018	Multicenter Scandinavian	48	87–92	23 [17]	68	34	9.1 ^{^^}	NR	NR	NR

†, results reported in one patient. [^], 6 months after resection. ^B, patient follow-up at least 90 days after stage-2. ^C, (Mean ± SD). ^D, recurrence developed in 2 patients. ^E, median disease-free survival (DFS) was 14.6 months. ^F, expressed as mean. ^{*}, two postoperative deaths are excluded. ^{**}, after the two-stage operation. ^{***}, expressed for type of tumor. CLRM/Biliary tumors/HCC. ⁺, expressed in severe morbidity (≥ IIIb). ⁺⁺, expressed as total of majors complications (≥ III)/total of complications. ⁻, at 1 year of follow-up. [^], at 2 years of follow-up. ^{^^}, at 90 day follow-up. ^{^^^}, expressed by stages. ⁻⁻⁻, at 3 years of follow-up; [#], expressed in absolute numbers; [/], liver cirrhosis–normal livers; ^{//}, Charlson index, mean ± SD. Dindo-Clavien Classification was used (≥ III): total of complicated patients (≥ III)/total patients. FLR, future liver remnant; major morbidity; OFS, overall free survival; OS, overall survival; NR, unreported.

References

- Donati M, Stavrou GA, Basile F, et al. Combination of in situ split and portal ligation: lights and shadows of a new surgical procedure. *Ann Surg* 2012;256:e11-2; author reply e16-9.
- Dokmak S, Belghiti J. Which limits to the "ALPPS" approach? *Ann Surg* 2012;256:e6; author reply e16-7.
- Li J, Girotti P, Königsrainer I, et al. ALPPS in right trisectionectomy: a safe procedure to avoid postoperative liver failure? *J Gastrointest Surg* 2013;17:956-61.
- Björnsson B, Sparrelid E, Røskok B, et al. Associating liver partition and portal vein ligation for staged hepatectomy in patients with colorectal liver metastases--Intermediate oncological results. *Eur J Surg Oncol* 2016;42:531-7.
- Vivarelli M, Vincenzi P, Montalti R, et al. ALPPS Procedure for Extended Liver Resections: A Single Centre Experience and a Systematic Review. *PLoS One* 2015;10:e0144019.
- Vennarecci G, Grazi GL, Sperduti I, et al. ALPPS for primary and secondary liver tumors. *Int J Surg* 2016;30:38-44.
- Vennarecci G, Ferraro D, Tudisco A, et al. The ALPPS procedure: hepatocellular carcinoma as a main indication. An Italian single-center experience. *Updates Surg* 2019;71:67-75.